Tessera Defense & Homeland Security Inc. (HLSQ)
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
Sector: Services-Prepackaged Software
Industry: Biotechnology
Tessera Defense and Homeland Security Inc
No financial data available.
No debt & equity data available.
Nasdaq bars a compliance period at 1:250
- 1:10Reverse splitSep 9, 202610 shares → 1
No balance sheet details available.
No income statement data available.
No balance sheet data available.
No cash flow data available.